AUSTRALIA lower dosages , less side effects and a quicker onset of action .
“ Because the lining of the mouth is highly vascularized , the drug is absorbed directly into the blood system , avoiding hepatic first metabolism and the gastrointestinal tract ,” said Woolf . “ This can provide enhanced bioavailability — meaning you need less of the drug to get the same amount absorbed into the blood system and with quicker onset of action .”
“ We also avoid the need for patients to have to swallow — which is important for pediatrics and geriatrics , as well as when nausea or vomiting is involved . We formulate our sprays with flavours and tastes for a pleasant patient experience , which gives better compliance and convenience .”
SUDA ’ s pipeline of sprays include ZolpiMist ® — the same active that is administered in tablet form as Ambien ® or Stilnox ® — which is used to treat insomnia . The product is registered in the U . S . and is expected to be launched in 2016 , and SUDA is currently speaking with pharmaceutical companies in other
Oro-mucosal drug
parts of the world to license the drug .
In addition , a sublingual spray for treating pediatric malaria called ArTiMist™ has completed a Phase III study , where it was compared to intravenous quinine . The results from this study confirmed that SUDA ’ s spray was superior .
SUDA is in dialogue with The World Health Organisation ( WHO ) and other philanthropic groups to make the drug accessible in malaria epidemic countries , as well as expanding the use of the product to include early interventional treatment in the pre-referral setting . Other key products in SUDA ’ s
www
. sudaltd . com . au 47